| Field |
Value |
Language |
|
dc.contributor.author |
Malyla, V |
|
|
dc.contributor.author |
De Rubis, G |
|
|
dc.contributor.author |
Paudel, KR |
|
|
dc.contributor.author |
Chellappan, DK |
|
|
dc.contributor.author |
Hansbro, NG |
|
|
dc.contributor.author |
Hansbro, PM |
|
|
dc.contributor.author |
Dua, K |
|
|
dc.date.accessioned |
2023-06-03T23:45:19Z |
|
|
dc.date.available |
2023-06-03T23:45:19Z |
|
|
dc.identifier.citation |
Naunyn-Schmiedeberg's Archives of Pharmacology |
|
|
dc.identifier.issn |
0028-1298 |
|
|
dc.identifier.issn |
1432-1912 |
|
|
dc.identifier.uri |
http://hdl.handle.net/10453/170599
|
|
|
dc.description.abstract |
<jats:title>Abstract
</jats:title><jats:p>Lung cancer (LC) is the leading cause of cancer-related deaths globally. It accounts for more than 1.9 million cases each year due to its complex and poorly understood molecular mechanisms that result in unregulated cell proliferation and metastasis. β-Catenin is a developmentally active protein that controls cell proliferation, metastasis, polarity and cell fate during homeostasis and aids in cancer progression via epithelial–mesenchymal transition. Therefore, inhibition of the β-catenin pathway could attenuate the progression of LC. Berberine, an isoquinoline alkaloid which is known for its anti-cancer and anti-inflammatory properties, demonstrates poor solubility and bioavailability. In our study, we have encapsulated berberine into liquid crystalline nanoparticles to improve its physiochemical functions and studied if these nanoparticles target the β-catenin pathway to inhibit the human lung adenocarcinoma cell line (A549) at both gene and protein levels. We observed for the first time that berberine liquid crystalline nanoparticles at 5 µM significantly attenuate the expression of the β-catenin gene and protein. The interaction between berberine and β-catenin was further validated by molecular simulation studies. Targeting β-catenin with berberine nanoparticles represents a promising strategy for the management of lung cancer progression.
</jats:p> |
|
|
dc.language |
en |
|
|
dc.publisher |
Springer Science and Business Media LLC |
|
|
dc.relation |
Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE)-- |
|
|
dc.relation |
Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE)TRIPLE I CAG SECONDMENT / EXCHANGE |
|
|
dc.relation |
Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) |
|
|
dc.relation |
Maridulu Budyari Gumal - The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE)N/A |
|
|
dc.relation.ispartof |
Naunyn-Schmiedeberg's Archives of Pharmacology |
|
|
dc.relation.isbasedon |
10.1007/s00210-023-02553-y |
|
|
dc.rights |
info:eu-repo/semantics/openAccess |
|
|
dc.subject |
1115 Pharmacology and Pharmaceutical Sciences, 1116 Medical Physiology |
|
|
dc.subject.classification |
Pharmacology & Pharmacy |
|
|
dc.title |
Berberine nanostructures attenuate ß-catenin, a key component of epithelial mesenchymal transition in lung adenocarcinoma |
|
|
dc.type |
Journal Article |
|
|
utslib.for |
1115 Pharmacology and Pharmaceutical Sciences |
|
|
utslib.for |
1116 Medical Physiology |
|
|
pubs.organisational-group |
/University of Technology Sydney |
|
|
pubs.organisational-group |
/University of Technology Sydney/Faculty of Science |
|
|
pubs.organisational-group |
/University of Technology Sydney/Strength - CFI - Centre for Inflammation |
|
|
utslib.copyright.status |
open_access |
* |
|
dc.date.updated |
2023-06-03T23:45:17Z |
|
|
pubs.publication-status |
Published online |
|
